During the open-label extension , all participants received OM 40/AML 5/HCTZ 12.5 mg ; participants not reaching BP goal within 2 weeks were randomly titrated to OM 40/AML 10/HCTZ 12.5 mg or OM 40/AML 5/HCTZ 25 mg , then to OM 40/AML 10 / HCTZ 25 mg after another 2 weeks .